Recurrent panniculitis in a man with asthma receiving treatment with leukotriene-modifying agents.
Leukotriene-modifying drugs are novel agents introduced recently to treat asthma. Both 5-lipoxygenase inhibitors, such as zileuton, and leukotriene receptor antagonists, such as zafirlukast and montelukast, have proved effective in the treatment of asthma. To our knowledge, there have been no detailed reports regarding dermatologic manifestations of this class of drugs. This article describes an unusual case of erythema nodosum in a 46-year-old asthmatic man who received 2 different leukotriene modifiers.
Dellaripa
P F
PF
Division of Rheumatology, Lahey Clinic, Burlington, Mass 01805, USA.
Wechsler
M E
ME
Roth
M E
ME
Drazen
J
J
D000085:Acetates / Q000009:adverse effects*; D018927:Anti-Asthmatic Agents / Q000009:adverse effects*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001249:Asthma / Q000188:drug therapy*; D003521:Cyclopropanes; D003937:Diagnosis, Differential; D004891:Erythema Induratum / Q000139:chemically induced / Q000175:diagnosis*; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000031:analogs & derivatives*; D020024:Leukotriene Antagonists / Q000009:adverse effects*; D016859:Lipoxygenase Inhibitors / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010201:Panniculitis, Nodular Nonsuppurative / Q000139:chemically induced / Q000175:diagnosis*; D011804:Quinolines / Q000009:adverse effects*; D013440:Sulfides
D000085:Acetates; D018927:Anti-Asthmatic Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D016859:Lipoxygenase Inhibitors; D011804:Quinolines; D013440:Sulfides; C093875:montelukast; C063449:zileuton; D006918:Hydroxyurea